🔎 Trials Near Me

መነሻ › ኒውሮብላስቶማ › Texas

በTexas ለኒውሮብላስቶማ የሚደረጉ ክሊኒካዊ ጥናቶች

ለኒውሮብላስቶማ የሚደረጉ 15 ጥናቶች በTexas ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በTexas ውስጥ ያሉ ከተሞች

Official study text (English)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • Medical City Dallas Hospital, Dallas
  • እና 10 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እስከ እድሜ 30 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06172296

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • University of Texas MD Anderson Cancer Center ( Site 1007), Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
6 Months – 25 Years · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT06395103

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  • Dell Children's Blood and Cancer Center, Austin
  • Children's Medical Center, Dallas
ተሳታዮችን በመፈለግ ላይደረጃ 2
እስከ እድሜ 22 · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT02559778

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

  • Children's Medical Center, Dallas
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እስከ እድሜ 26 · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06465199

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • Children's Medical Center, Dallas
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እስከ እድሜ 30 · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06541262

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

  • Dell Children's Blood and Cancer Center, Austin
  • Children's Medical Center, Dallas
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ1 እስከ 21 · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06540963

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • እና 8 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
365 Days – 30 Years · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
12 Months – 30 Years · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04851119

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

  • Dell Children's Blood and Cancer Center, Austin
ተሳታዮችን በመፈለግ ላይደረጃ 2
12 Months – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ12 ኦገስ 2026 · NCT05489887

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

  • Texas Children's Hospital, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ ከ1 እስከ 30 · ሁሉም ጾታዎች · የተሻሻለው በ22 ጁላይ 2026 · NCT06721689

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

  • Texas Children's Hospital, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ1 እስከ 24 · ሁሉም ጾታዎች · የተሻሻለው በ21 ጁላይ 2026 · NCT07211737

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

  • University of Texas Southwestern, Dallas
  • Cook Children's Medical Center, Fort Worth
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ1 እስከ 31 · ሁሉም ጾታዎች · የተሻሻለው በ20 ጁላይ 2026 · NCT06450041

Neuroblastoma Biology Study

  • University of Texas Southwestern, Dallas
  • Cook Children's Medical Center - Fort Worth, Fort Worth
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
31 Days – 99 Years · ሁሉም ጾታዎች · የተሻሻለው በ23 ማርች 2026 · NCT01587300

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

  • University of Texas Southwestern Medical Center, Dallas
ተሳታዮችን በመፈለግ ላይ
እስከ እድሜ 17 · ሁሉም ጾታዎች · የተሻሻለው በ10 ፌብሩ 2026 · NCT06831552

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma

  • Texas Children's Hospital, Houston
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ1 እስከ 21 · ሁሉም ጾታዎች · የተሻሻለው በ19 ሴፕቴ 2025 · NCT03294954

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።